<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789708</url>
  </required_header>
  <id_info>
    <org_study_id>016227</org_study_id>
    <nct_id>NCT03789708</nct_id>
  </id_info>
  <brief_title>Effects of Gum Arabic Supplementation in Hemodialysis Patients</brief_title>
  <official_title>Study of Some Pharmacological and Biochemical Effects of Gum Arabic Supplementation to Hemodilaysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Kidney Diseases and Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Almughtaribeen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Khartoum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gum Arabic is a naturally produced gummy exudate from Acacia Senegal tree. It's a complex
      polysaccharide with proven prebiotic properties. Through its effect on intestinal bacteria,
      it's expected to reduce systemic levels of toxic bacterial metabolites and reduce
      inflammatory markers.By increasing fecal bacteria mass it's also expected to reduce blood
      urea level. These changes are potentially beneficial to hemodialysis patients who suffer from
      disturbed intestinal flora and a chronic inflammatory status. The investigators hypothesize
      that supplementing the diet of hemodialysis patients with Gum Arabic for four weeks would
      reduce inflammatory markers, increase total anti-oxidant capacity and reduce blood urea
      concentration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized and controlled clinical trial with parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The placebo and the Gum Arabic are provided to patients in similar unlabeled packages</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Highly sensitive C-reactive protein (hs CRP) level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum level of highly sensitive C-reactive protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total anti-oxidant capacity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum total anti-oxidant capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood urea level</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in urea blood level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum calcium level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum phosphorus level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum uric acid level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 20 g of Gum Arabic supplementation daily for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 40 g of Gum Arabic supplementation daily for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gum Arabic</intervention_name>
    <description>Instantly soluble granules of Gum Arabic; 100% Acacia Senegal</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin powder, easily soluble</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult end-stage renal disease patients maintained on regular hemodialysis

        Exclusion Criteria:

          -  Chronic liver disease

          -  Malignant condition

          -  Inflammatory bowel disease

          -  History of bowel resection

          -  Long term antibiotic therapy

          -  Pregnancy or lactation

          -  Current use of immunosuppressive medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarra Elamin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Nephrologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Doctor Salma Center for Kidney Diseases</name>
      <address>
        <city>Khartoum</city>
        <zip>11111</zip>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>December 31, 2018</last_update_submitted>
  <last_update_submitted_qc>December 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Khartoum</investigator_affiliation>
    <investigator_full_name>Sarra Elamin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

